Hepion Pharmaceuticals, Inc.

HEPA Details

Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA)  is a clinical-stage biopharmaceutical company focused on treating chronic liver disorders such as liver fibrosis, hepatocellular carcinoma (HCC), viral hepatitis, and other liver infections. The company's primary drug, CRV431, aids in the decrease of liver fibrosis and inhibits the formation of cancerous tumors. It also has antiviral properties against chronic hepatitis virus infection (HBV, HCV and HDV). Recently, the CRV 431 drug has been shown to play a significant role in the comprehensive treatment of liver illnesses, from the early stages to the final stages.

Latest News:

• Step Towards Regulatory Approval: On December 21, 2021, the US Food and Drug Administration (FDA) has accepted HEPA's investigational new drug (IND) application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (HCC) in the United States. The IND clearance allows CRV431 to go directly to Phase 2 to treat HCC.

Q3FY21 Results:

• No Visibility in Topline: HEPA didn't report any revenue in Q3FY21.
• Increase in R&D Expenses: The company incurred research and development (R&D) expenses of USD 5.80 million in Q3FY21 compared to USD 3.78 million in Q3FY20. Higher spending on ongoing studies and clinical trials, consulting fees, and increasing employee compensation costs contributed to the increase.
• Expansion of Net Losses: The company's net loss increased to USD 9.27 million in Q3FY21 from USD 6.24 million in Q3FY20.
• Cash and Debt Position: As of September 30, 2021, the company had cash and cash equivalents of USD 98.73 million and no outstanding debt.

Key Risks:

• Competition Risk: HEPA's prospects are significantly dependent on the commercial success of its sole product candidate, CRV431. It has invested a considerable amount of resources in its development, and if it fails to obtain the marketing approval or put an efficient manufacturing and distribution mechanism in place, its results of operations could be adversely impacted.
• Dependence On Third-party Manufacturers: HEPA does not have its manufacturing facility and depends on third-party suppliers to manufacture its drugs. It could jeopardize its capacity to meet product demand and, as a result, the company's overall performance.

HEPA Daily Technical Chart (Source: REFINITIV)

Stock Recommendation:

HEPA's stock price has declined 38.13% in the past twelve months and is currently leaning towards the lower band of its 52-week range of USD 1.12 to USD 3.18. The stock is currently trading below its 50 and 200 DMA levels, and its RSI Index is at 58.92.

Considering the correction in the stock price in the past twelve months, progress towards regulatory approval, and associated risks, we recommend a "Speculative Buy" rating on the stock at the current price of USD 1.36, up 10.16% as of December 22, 2021, 03:06 PM ET.

* The reference data in this report has been partly sourced from REFINITIV.

* All forecasted figures and industry information have been taken from REFINITIV.

*Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached.  

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.